{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:05:20Z","timestamp":1772669120467,"version":"3.50.1"},"reference-count":17,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>C\u2013C Motif Chemokine Ligand 17 (CCL17) is a chemokine that binds and signals through the G\u2010protein coupled CC\u2010chemokine receptor 4 and has been implicated in the development of inflammatory and arthritic pain. GSK3858279 is a high\u2010affinity, first\u2010in\u2010class, monoclonal antibody, binding specifically to CCL17 and inhibiting downstream signaling. In this phase I, randomized, single\u2010center, double\u2010blind, placebo\u2010controlled, three\u2010period, incomplete\u2010block crossover study (NCT04114656), the analgesic effects and safety of intravenous GSK3858279 were assessed in a battery of evoked acute pain assessments on healthy, adult (aged \u226518\u2009years), male participants. Participants were randomized 1:1 to receive either one placebo (0.9% w\/v NaCl) dose followed by two GSK3858279 doses (PAA treatment sequence), or one GSK3858279 dose followed by two placebo doses (APP treatment sequence). The co\u2010primary end points were ultraviolet B heat pain detection threshold (\u00b0C), cold pressor time to pain tolerance threshold (PTT, sec), and electrical PTT (mA, single stimulus). Twenty\u2010one participants were enrolled (PAA\u2009=\u200911; APP\u2009=\u200910). Mean age (standard deviation) was 29.3 (7.9) years for PAA, 31.1 (7.7) years for APP. No significant differences were observed in the analgesic effect between GSK3858279 and placebo for any end point. Exposure to GSK3858279 was similar between Period 1 (APP sequence), and Periods 2 and 3 (PAA sequence), with some GSK3858279 carry\u2010over. Changes in serum CCL17 levels were consistent with the expected GSK3858279 activity. All drug\u2010related adverse events were mild in intensity and caused no discontinuations. The absence of an efficacy signal in this acute pain model does not preclude efficacy in chronic pain states.<\/jats:p>","DOI":"10.1111\/cts.13873","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T16:40:17Z","timestamp":1725900017000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Randomized, placebo\u2010controlled study on the effects of intravenous GSK3858279 (anti\u2010CCL17) on a battery of evoked pain tests in healthy participants"],"prefix":"10.1111","volume":"17","author":[{"given":"Yvonne","family":"Boyle","sequence":"first","affiliation":[{"name":"GSK  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7298-8650","authenticated-orcid":false,"given":"Hemme J.","family":"Hijma","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research  Leiden The Netherlands"},{"name":"Leiden University Medical Centre  Leiden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9581-6229","authenticated-orcid":false,"given":"Jamie","family":"Rees","sequence":"additional","affiliation":[{"name":"GSK  Brentford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4947-6299","authenticated-orcid":false,"given":"Jagtar","family":"Nijjar","sequence":"additional","affiliation":[{"name":"GSK  Stevenage UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eirini","family":"Panoilia","sequence":"additional","affiliation":[{"name":"GSK  Stevenage UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6367-0165","authenticated-orcid":false,"given":"Yolanda","family":"Alvarez","sequence":"additional","affiliation":[{"name":"GSK  Brentford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6408-7393","authenticated-orcid":false,"given":"Sarah","family":"Siederer","sequence":"additional","affiliation":[{"name":"GSK  Stevenage UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Greening","sequence":"additional","affiliation":[{"name":"GSK  Brentford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9723-8661","authenticated-orcid":false,"given":"Edward","family":"Emery","sequence":"additional","affiliation":[{"name":"GSK  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1470-7368","authenticated-orcid":false,"given":"Kathy","family":"Abbott\u00a0Banner","sequence":"additional","affiliation":[{"name":"GSK  Brentford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4655-6667","authenticated-orcid":false,"given":"Geert Jan","family":"Groeneveld","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research  Leiden The Netherlands"},{"name":"Leiden University Medical Centre  Leiden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000315"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI87828"},{"issue":"6","key":"e_1_2_11_4_1","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99249","article-title":"TNF and granulocyte macrophage\u2010colony stimulating factor interdependence mediates inflammation via CCL17","volume":"3","author":"Cook AD","year":"2018","journal-title":"JCI Insight"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxu079"},{"issue":"7","key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/ejp.1222","article-title":"Effect profile of paracetamol, Delta9\u2010THC and promethazine using an evoked pain test battery in healthy subjects","volume":"22","author":"Amerongen G","year":"2018","journal-title":"Eur J Pain"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.1353"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnab032"},{"issue":"5","key":"e_1_2_11_9_1","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/bcp.13183","article-title":"The use of a battery of pain models to detect analgesic properties of compounds: a two\u2010part four\u2010way crossover study","volume":"83","author":"Okkerse P","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15505"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.1379"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43586-020-00001-2"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30471-9"},{"issue":"5","key":"e_1_2_11_14_1","doi-asserted-by":"crossref","first-page":"576","DOI":"10.4161\/mabs.2.5.12833","article-title":"Properties of a general PK\/PD model of antibody\u2010ligand interactions for therapeutic antibodies that bind to soluble endogenous targets","volume":"2","author":"Davda JP","year":"2010","journal-title":"MAbs"},{"issue":"6","key":"e_1_2_11_15_1","first-page":"587","article-title":"Human experimental pain models: a review of standardized methods in drug development","volume":"17","author":"Reddy KS","year":"2012","journal-title":"J Res Med Sci"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.111.005447"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13448"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24031866"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T16:40:24Z","timestamp":1725900024000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1111\/cts.13873"],"URL":"https:\/\/doi.org\/10.1111\/cts.13873","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"2024-01-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13873"}}